ClinicalTrials.gg
CompletedNCT04042363ONSTIMUpdated Nov 17, 2026

Effect of Transorbital Electrical STIMulation of Optic Nerve on Remyelination After an Acute Optic Neuritis

An interventional study of Transorbital electrical stimulation (Eyetronic Next Wave 1.1) and Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation in Multiple Sclerosis and Optic Neuritis, sponsored by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. Completed at 2 sites in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 376 studies in Multiple Sclerosis with a site in France — 63 open to participants now, 92 under way, 18 of them phase 3. Multiple Sclerosis · France.

Enrollment
192nd of 244
55 · median 144
Started
2019
with 28 others
No phase
110 of 376
32 open now
Registered
215th of 376
by date

Among the 376 studies in Multiple Sclerosis with a site in France, this one is the 192nd largest by enrollment of the 244 interventional ones that give a count, is one of 29 that started in 2019, is one of 110 with no phase, and was the 215th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

63 of the 376 studies in Multiple Sclerosis with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Multiple Sclerosis with a site in France, or all of them as a file.
02

Study summary

In light of experimental models showing that neuronal electrical activity is crucial for the remyelination process, we hypothesize that maintenance of electrical axonal activity in the early stages of optic neuritis may promote myelin repair, limiting thereby axonal degeneration.

In humans, electrical stimulation of the optic nerve has been tested mainly in ischemic neuropathy and retinitis pigmentosa, which are both associated with severe axonal/retinal pathology and poor visual prognosis. In contrast, the inflammation of the optic nerve in optic neuritis is generally transient, with less severe axonal damage at the acute phase, which would allow for better efficacy of electrical stimulation as a strategy to promote remyelination and neuroprotection.In light of experimental models showing that neuronal electrical activity is crucial for the remyelination process, we hypothesize that maintenance of electrical axonal activity in the early stages of optic neuritis may promote myelin repair, limiting thereby axonal degeneration.

Read the detailed description

This is a randomized, controlled, prospective, interventional, blinded trial which aims to evaluate the safety and efficacy of transorbital electrical nerve stimulation on remyelination and neuroprotection after an acute episode of retrobulbar optic neuritis in patients with multiple sclerosis (MS).

Expected Explorations: The study is composed of 14 visits: a screening/inclusion visit with neurological and ophthalmological evaluation, electrophysiology, MRI and Magnetoencephalography (MEG), 10 transorbital electrical stimulation or sham stimulation visits and finally 3 follow-up visits and evaluations (neurological and ophthalmological). Patient's participation will last 49 weeks (inclusion visit and 48 weeks of follow-up). Participation of healthy volunteers will last one day.

MS patients diagnosed with an optic neuritis will be randomized either in the active arm (transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks) or in the placebo arm (sham stimulation - 10 sessions during 2 consecutive weeks) Expected benefits: Electrical stimulation of the optic nerve after an acute episode of retrobulbar optic neuritis may promote remyelination in the optic nerve and a better long-term visual outcome.

03

Conditions studied

  • Multiple Sclerosis
  • Optic Neuritis

Keywords

  • multiple sclerosis
  • optic neuritis
  • transorbital stimulation
  • remyelination
  • nervous system disease
  • peripheral nervous system disease
  • optic nerve disease
  • adaptive optic
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For MS patients:
  • Age between 18 and 60 years old;
  • Relapsing Remitting MS (criteria of McDonald 2017) evolving for less than 10 years or Clinically Isolated Syndrome (CIS)-MS with criteria of spatial dissemination on MRI;
  • Subject presenting an acute unilateral episode of optic neuritis treated optimally (bolus of and plasma exchanges if considered necessary);
  • Last medical treatment for optic neuritis (NORB) received between 15 and 90 days before inclusion;
  • Patient not fully recovered from the NORB episode (high- or low-contrast AV abnormality, persistent visual field deficit);
  • Subject affiliated with or covered by a social security scheme.
  • Subject not affiliated with or a beneficiary of a social security scheme, unless an exemption granted by the Ethics Committee (CPP) following a request for derogation.

For Healthy Volunteers:

  • Age between 18 and 60 years old.
  • No history of neurological or ophthalmological diseases
  • Corrected visual acuity ≥ 8/10
  • affiliated with or beneficiary of a social security scheme.

Exclusion criteria

Exclusion Criteria:

For patients:

  • Differential diagnosis of Optic neuritis:

    i) Atypical acute optic neuritis (papillitis, severe papilledema, initial optic atrophy) ii) Optic neuromyelitis iii) Normal VEP during the inclusion visit iv) No detection of VEP during the inclusion visit

  • Impossibility to perform MRI, MEG, or electrical stimulation:

Pacemaker or neurosensory stimulator or implantable defibrillator Clip on an aneurysm or clip on a vascular malformation of the brain Cochlear implants Ocular or cerebral ferromagnetic foreign bodies Metal prostheses or metal clips or splinters Ventriculoperitoneal neurosurgical bypass valves Permanent makeup of the eyelids or lips Black tattoo, important and close to the cranio-facial sphere. Copper Intrauterine Device Person with proven claustrophobia Epilepsy Brain tumor Intraocular pressure without specific treatment Hypertension without treatment Acute retinal hemorrhage Periorbital skin irritation Significant cognitive deficit Known gadolinium allergy

  • Person with severe or uncontrolled symptoms of kidney, liver, hematological, gastrointestinal, pulmonary or cardiac disease or any uncontrolled intercurrent disease at the time of inclusion;
  • Pregnant or breath-feeding woman;
  • person under judicial protection or deprived of liberty.

For healthy volunteers:

  • to MRI or MEG
  • Person with severe or uncontrolled symptoms of kidney, liver, hematological disease, gastrointestinal, pulmonary or cardiac disease or any uncontrolled intercurrent pathology at the time of inclusion.
  • Pregnant or breath-feeding woman.
  • Person under the protection of justice or deprived of liberty
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Active Transorbital electrical stimulation

    Transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks

    Device: Transorbital electrical stimulation (Eyetronic Next Wave 1.1)

  • Sham comparator
    Sham Transorbital stimulation

    Sham stimulation - 10 sessions during 2 consecutive weeks

    Device: Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation

Interventions

  • DeviceTransorbital electrical stimulation (Eyetronic Next Wave 1.1)

    Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous. Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds.

  • DeviceTransorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation

    The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will not start the stimulation session.

06

What researchers measure

Primary outcomes

  1. P100 latency (VEP) after treatment

    Modification of the latency of P100 wave measured by Visual Evoked Potential (VEP) after 24 weeks of treatment with electrical or sham stimulation.

    Time frame: 24 weeks

Secondary outcomes

  1. Change of P100 amplitude (VEP) after treatment

    Modification of the amplitude of P100 wave measured by Visual Evoked Potential (VEP) after 24 weeks of treatment with electrical or sham stimulation.

    Time frame: 24 weeks

  2. Change of P100 latency and amplitude (VEP) after treatment

    Modification of the latency and amplitude of P100 wave measured by Visual Evoked Potential (VEP) after 12 and 48 weeks of treatment with electrical or sham stimulation.

    Time frame: 12 and 48 weeks

  3. Evolution of macular volume after treatment

    Evolution since inclusion of macular volume (with Optical Coherence Tomography) at weeks 12, 24 and 48 after transorbital electrical treatment or sham stimulation.

    Time frame: 12, 24 and 48 weeks

  4. Change of mean and temporal Retinal Nerve Fiber Layer (RNFL) thickness and average thickness of macular ganglion cell layer after treatment

    Evolution since inclusion of mean and temporal Retinal Nerve Fiber Layer (RNFL) thickness and average thickness of macular ganglion cell layer (with Optical Coherence Tomography) at weeks 12, 24 and 48 after transorbital electrical treatment or sham stimulation.

    Time frame: 12, 24 and 48 weeks

  5. Change of average thickness of macular ganglion cell layer after treatment

    Evolution since inclusion of average thickness of macular ganglion cell layer (with Optical Coherence Tomography) at weeks 12, 24 and 48 after transorbital electrical treatment or sham stimulation.

    Time frame: 12, 24 and 48 weeks

  6. Change of mean deflection of visual field 24-2 after treatment

    Change in the mean deflection of visual field 24-2 (24-2 Humphrey visual field analyser) at weeks 12, 24 and 48 compared to inclusion after electrical treatment or sham stimulation.

    Time frame: 12, 24 and 48 weeks

  7. Occurrence of adverse events related or not to the stimulation

    Reporting of adverse events related or not to the stimulation

    Time frame: through study completion, an average of 3 years

07

Study locations

2 sites
  • Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
    Paris, 75012, France
  • Institut du Cerveau et de la Moelle epiniere - Hopital Pitie Salpetriere
    Paris, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Feb 2023, 42 months.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 42 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Jul 2019 → Aug 2019, primary completion Jul 2021 → Feb 2023 and completion Jul 2022 → Jul 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Aug 1, 2019
StartActual
Aug 6, 2019was Jul 2019
Primary completionActual
Feb 8, 2023was Jul 2021
CompletionActual
Jul 17, 2024was Jul 2022
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Start date
Jul 10, 2019→Aug 6, 2019
Nov 17, 2026
Primary completion
Jul 2021→Feb 8, 2023 (actual)
Nov 17, 2026
Study completion
Jul 2022→Jul 17, 2024 (actual)
Nov 17, 2026
Enrollment
45 (estimated)→55 (actual)
Nov 17, 2026
Eligibility
2 inclusion criteria edited, 3 added, 2 removed; 2 exclusion criteria removed
What changed in the criteria
Inclusion criteria
  • EditedLast medical treatment for optic neuritis (NORB) received between 3015 and 90 days before inclusion;
  • RemovedVisual acuity <7/10 of the affected eye at the time of inclusion
  • RemovedSocial security scheme or beneficiary of such a scheme
  • AddedPatient not fully recovered from the NORB episode (high- or low-contrast AV abnormality, persistent visual field deficit);
  • AddedSubject affiliated with or covered by a social security scheme.
  • AddedSubject not affiliated with or a beneficiary of a social security scheme, unless an exemption granted by the Ethics Committee (CPP) following a request for derogation.
  • EditedSchemeaffiliated with or beneficiary of such a social security scheme.
Exclusion criteria
  • RemovedRefusal of the participant to be informed in case of fortuitous discoveries having a direct impact on his health and requiring appropriate care
  • RemovedRefusal of the participant to be informed in case of fortuitous discoveries having a direct impact on his health and requiring appropriate care
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Start date Jul 10, 2019→Aug 6, 2019
    Primary completion Jul 2021→Feb 8, 2023 (now actual)
    Study completion Jul 2022→Jul 17, 2024 (now actual)
    Enrollment 45 (estimated)→55 (actual)
    Eligibility 2 inclusion criteria edited, 3 added, 2 removed; 2 exclusion criteria removed
    What changed in the criteria
    Inclusion criteria
    • EditedLast medical treatment for optic neuritis (NORB) received between 3015 and 90 days before inclusion;
    • RemovedVisual acuity <7/10 of the affected eye at the time of inclusion
    • RemovedSocial security scheme or beneficiary of such a scheme
    • AddedPatient not fully recovered from the NORB episode (high- or low-contrast AV abnormality, persistent visual field deficit);
    • AddedSubject affiliated with or covered by a social security scheme.
    • AddedSubject not affiliated with or a beneficiary of a social security scheme, unless an exemption granted by the Ethics Committee (CPP) following a request for derogation.
    • EditedSchemeaffiliated with or beneficiary of such a social security scheme.
    Exclusion criteria
    • RemovedRefusal of the participant to be informed in case of fortuitous discoveries having a direct impact on his health and requiring appropriate care
    • RemovedRefusal of the participant to be informed in case of fortuitous discoveries having a direct impact on his health and requiring appropriate care
    + 5 other changes: verification date, description, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04042363
Lead sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Collaborators
Fondation ARSEP, APHP
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Aug 6, 2019
Primary completion
Feb 8, 2023
Completion
Jul 17, 2024
Last update
Nov 17, 2026

Study contacts

Céline Louapre
principal investigator · Institut du Cerveau et de la Moelle Epiniere, Pitie Salpetriere Hospital, Paris
Michel PAQUES
principal investigator · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion